Document Detail


Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
MedLine Citation:
PMID:  18082989     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To compare the diagnostic accuracy for the detection of tumor recurrence in breast cancer patients using whole-body-MRI (WB-MRI) at 1.5 or 3T compared to FDG-PET-CT. MATERIALS AND METHODS: Thirty-three female patients with breast cancer and suspicion of recurrence underwent FDG-PET-CT and WB-MRI. Coronal T1w-TSE- and STIR-sequences, HASTE-imaging of the lungs, contrast-enhanced T1w- and T2w-TSE-sequences of the liver, brain and abdomen were performed, using a WB-MRI-scanner at 1.5 (n=23) or 3T (n=10). Presence of local recurrence, lymph node involvement and distant metastatic disease was assessed using clinical and radiological follow-up as a standard of reference. RESULTS: Tumor recurrence was found in 20 of 33 patients. Overall 186 malignant foci were detected with WB-MRI and PET-CT. Both modalities revealed two recurrent tumors of the breast. PET-CT detected more lymph node metastases (n=21) than WB-MRI (n=16). WB-MRI was more precise in the detection of distant metastases (n=154 versus n=147). Sensitivity was 93% (172/186) and 91% (170/186) for WB-MRI and PET-CT, specificity was 86% (66/77) and 90% (69/77), respectively. Examination times for WB-MRI at 1.5 and 3T were 51 and 43 min, respectively, examination time for PET-CT was 103 min. CONCLUSION: WB-MRI and PET-CT are useful for the detection of tumor recurrence in the follow-up of breast cancer. WB-MRI is highly sensitive to distant metastatic disease. PET-CT is more sensitive in detecting lymph node involvement. Tumor screening with WB-MRI is feasible at 1.5 and 3T, scan time is further reduced at 3T with identical resolution.
Authors:
Gerwin P Schmidt; Andrea Baur-Melnyk; Alexander Haug; Volker Heinemann; Ingo Bauerfeind; Maximilian F Reiser; Stefan O Schoenberg
Related Documents :
10999049 - The role of radiation in the management of hodgkin's disease: an update.
17311309 - Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18f-fdg pet/ct ...
11694779 - Positron emission tomography and lymphoma therapy.
16724209 - Evaluation of the impact of addition of pet to ct and mr scanning in the staging of pat...
17584499 - 11c-choline vs. 18f-fdg pet/ct in assessing bone involvement in patients with multiple ...
9766719 - Computed tomography and positron emission tomography in the pre-operative staging of oe...
18173919 - What is the diagnostic value of ultrasonography compared to physical evaluation in pati...
740209 - Leukoencephalopathy following high-dose intravenous methotrexate chemotherapy: quantita...
10999049 - The role of radiation in the management of hodgkin's disease: an update.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2007-12-20
Journal Detail:
Title:  European journal of radiology     Volume:  65     ISSN:  0720-048X     ISO Abbreviation:  Eur J Radiol     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2008-01-08     Completed Date:  2008-04-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8106411     Medline TA:  Eur J Radiol     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  47-58     Citation Subset:  IM    
Affiliation:
Institute of Clinical Radiology, University Hospitals Munich-Grosshadern, Marchioninistr. 15, 81377 Munich, Germany. gerwin.schmidt@med.uni-muenchen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Breast Neoplasms / diagnosis*,  radiography,  radionuclide imaging
Contrast Media
Female
Fluorodeoxyglucose F18 / diagnostic use
Humans
Image Interpretation, Computer-Assisted
Iohexol / analogs & derivatives,  diagnostic use
Lymphatic Metastasis
Magnetic Resonance Imaging / methods*
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local / diagnosis*
Radiopharmaceuticals / diagnostic use
Sensitivity and Specificity
Tomography, Emission-Computed
Tomography, X-Ray Computed / methods*
Whole Body Imaging
Chemical
Reg. No./Substance:
0/Contrast Media; 0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18; 66108-95-0/Iohexol; 73334-07-3/iopromide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polish Centenarians Programme. Multidisciplinary studies of successful ageing: aims, methods, and pr...
Next Document:  Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for ...